Cleared Traditional

K120615 - ALERE CHOLESTECH LDX ANALYZER, ALERE CHOLESTECH LDX LIPID PROFILE - GLU CASSETTE

K120615 is an FDA 510(k) clearance for ALERE CHOLESTECH LDX ANALYZER, manufactured by Alere San Diego Inc. Dba Biosite,Innovacon,Hemosen. The device is a Class 2 Chemistry device with product code CGA cleared through the Traditional 510(k) pathway after a 441-day FDA review.

K120615 · Alere San Diego Inc. Dba Biosite,Innovacon,Hemosen · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 2013
Decision
441d
Days
Class 2
Risk

K120615 is an FDA 510(k) clearance for the ALERE CHOLESTECH LDX ANALYZER, ALERE CHOLESTECH LDX LIPID PROFILE - GLU CASSETTE. Classified as Glucose Oxidase, Glucose (product code CGA), Class II - Special Controls.

Submitted by Alere San Diego Inc. Dba Biosite,Innovacon,Hemosen (San Diego, US). The FDA issued a Cleared decision on May 15, 2013 after a review of 441 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Alere San Diego Inc. Dba Biosite,Innovacon,Hemosen devices

FDA 510(k) Submission Details - K120615

510(k) Number K120615 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 29, 2012
Decision Date May 15, 2013
Days to Decision 441 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
353d slower than avg
Panel avg: 88d · This submission: 441d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

CGA Device Classification - Class 2, Special Controls

Product Code CGA Glucose Oxidase, Glucose
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CGA Glucose Oxidase, Glucose

All 305
Devices cleared under the same product code (CGA) and FDA review panel - the closest regulatory comparables to K120615.
IN TOUCH BLOOD GLUCOSE MONITORING SYSTEM
K133584 · Eoshealth, Inc. · Sep 2014
ARKRAY GLUCOCARD 01 BLOOD GLUCOSE MONITORING SYSTEM AND RELION CONFIRM BLOOD GLUCOSE MONITORING SYSTEM
K124021 · Arkray Factory, Inc. · Jun 2014
AUTOSURE HT BLOOD GLUCOSE MONITORING SYSTEM
K131750 · Apex BioTechnology Corp. · Mar 2014
BLOOD GLUCOSE MONITORING SYSTEM (GLUCOSE OXIDASE)
K113636 · Philosys Co., Ltd. · Mar 2013
FORA V10 BLOOD GLUCOSE MONITORING SYSTEM
K121706 · Foracare, Inc. · Jan 2013
ACON ON CALL VIVID PAL BLOOD GLUCOSE MONITORING SYSTEM
K122110 · ACON Laboratories, Inc. · Nov 2012